{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:19:08Z","timestamp":1782271148784,"version":"3.54.5"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.cpcardiol.2024.102372","type":"journal-article","created":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T05:43:33Z","timestamp":1706334213000},"page":"102372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The cardioprotective potential of sodium-glucose cotransporter 2-inhibitors in breast cancer therapy-related cardiac dysfunction \u2013 A systematic review"],"prefix":"10.1016","volume":"49","author":[{"given":"Jun Hua","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack Junjie","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tira Jing Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan Wai Kay","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mabel","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuh Yong","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Thuan Heng","family":"Chuah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2024.102372_bib0001","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.cpcardiol.2024.102372_bib0002","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.cpcardiol.2024.102372_bib0003","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.cpcardiol.2024.102372_bib0004","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102372_bib0005","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","article-title":"The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial","volume":"28","author":"Spertus","year":"2022","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.cpcardiol.2024.102372_bib0006","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.cpcardiol.2024.102372_bib0007","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2024.102372_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2019.06.004","article-title":"Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial","volume":"1","author":"Leong","year":"2019","journal-title":"JACC CardioOncology [Internet]"},{"issue":"7","key":"10.1016\/j.cpcardiol.2024.102372_bib0009","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J Clin Oncol [Internet]"},{"issue":"26","key":"10.1016\/j.cpcardiol.2024.102372_bib0010","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2024.102372_bib0011","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2011","journal-title":"N Engl J Med [Internet]"},{"issue":"19","key":"10.1016\/j.cpcardiol.2024.102372_bib0012","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cpcardiol.2024.102372_bib0013","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0025-6196(11)60896-3","article-title":"Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials","volume":"83","author":"Perez","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cpcardiol.2024.102372_bib0014","unstructured":"Genentech I. Herceptin Prescribing Information. 2010."},{"issue":"1","key":"10.1016\/j.cpcardiol.2024.102372_bib0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3747\/co.2008.199","article-title":"Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group","volume":"15","author":"Mackey","year":"2008","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2024.102372_bib0016","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002843","article-title":"Cancer therapy-related cardiac dysfunction and heart failure: part 2: prevention, treatment, guidelines, and future directions","volume":"9","author":"Hamo","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"24","key":"10.1016\/j.cpcardiol.2024.102372_bib0017","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.cpcardiol.2024.102372_bib0018","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1016\/S2214-109X(18)30306-1","article-title":"Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study","volume":"6","author":"Teng","year":"2018","journal-title":"Lancet Glob Heal"},{"issue":"20","key":"10.1016\/j.cpcardiol.2024.102372_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013389","article-title":"SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects","volume":"8","author":"Lam","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"10.1016\/j.cpcardiol.2024.102372_bib0020","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med [Internet]"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102372_bib0021","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2018","journal-title":"N Engl J Med [Internet]"},{"issue":"7","key":"10.1016\/j.cpcardiol.2024.102372_bib0022","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med [Internet]"},{"issue":"15","key":"10.1016\/j.cpcardiol.2024.102372_bib0023","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med [Internet]"},{"key":"10.1016\/j.cpcardiol.2024.102372_bib0024","unstructured":"Empagliflozin in the prevention of cardiotoxicity in cancer patients undergoing chemotherapy based on anthracyclines [Internet]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05271162."},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102372_bib0025","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/hrt.75.4.330","article-title":"Cardioprotection: definition, classification, and fundamental principles","volume":"75","author":"K\u00fcbler","year":"1996","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2024.102372_bib0026","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.radcr.2022.12.048","article-title":"Delayed doxorubicin induced cardiomyopathy in a breast cancer patient: a case report","volume":"18","author":"Song","year":"2023","journal-title":"Radiology Case Reports. Netherlands"},{"issue":"Supplement_D","key":"10.1016\/j.cpcardiol.2024.102372_bib0027","doi-asserted-by":"crossref","first-page":"D149","DOI":"10.1093\/eurheartjsupp\/suad111.354","article-title":"P280 teamwork is successful (1): favoureable re\u2013challenge of double anti\u2013her2 treatment in severe myocardial dysfunction in patient with advanced breast cancer and occult type II diabetes","volume":"25","author":"Valenti","year":"2023","journal-title":"Eur Hear J"},{"issue":"1","key":"10.1016\/j.cpcardiol.2024.102372_bib0028","article-title":"Diagnosis and management of cancer treatment-related cardiac dysfunction and heart failure in children","volume":"10","author":"Hegazy","year":"2023","journal-title":"Child (Basel, Switzerland)"},{"issue":"Supplement_2","key":"10.1016\/j.cpcardiol.2024.102372_bib0029","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac544.2590","article-title":"Use of emgliflozine in cardiotoxicity treatment. EMPACARD-treatment registry. Six-months follow-up","volume":"43","author":"Daniele","year":"2022","journal-title":"Eur Heart J"},{"issue":"S2","key":"10.1016\/j.cpcardiol.2024.102372_bib0030","first-page":"168","article-title":"Effects of SGLT2 inhibitors in diabetic patients receiving doxorubicin-based chemotherapy for breast cancer","volume":"24","author":"Abdelnabi","year":"2022","journal-title":"Eur J Hear Fail Conf Abstr Hear Fail 2022 World Congr Acute Hear Fail Madrid, Spain [Internet]"},{"key":"10.1016\/j.cpcardiol.2024.102372_bib0031","series-title":"Conf Abstr 36th Int Conf Pharmacoepidemiol andTherapeutic Risk Manag Virtual","first-page":"137","article-title":"Newer generation diabetes medications and cardiovascular outcomes among older women with breast cancer and diabetes. Pharmacoepidemiol Drug Safety","volume":"29","author":"Zhou","year":"2020"},{"issue":"45","key":"10.1016\/j.cpcardiol.2024.102372_bib0032","first-page":"S13","article-title":"New strategies and therapies for the prevention of heart failure in high-risk patients","author":"Hammond","year":"2022","journal-title":"Clin Cardiol"},{"issue":"7","key":"10.1016\/j.cpcardiol.2024.102372_bib0033","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamacardio.2021.1133","article-title":"Could flozins be the statins for risk-based primary prevention of heart failure?","volume":"6","author":"Freaney","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102372_bib0034","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.repc.2021.04.002","article-title":"One size does not fit all: also true for cardio-oncology","volume":"40","author":"Mendes","year":"2021","journal-title":"Revista portuguesa de cardiologia. Spain"},{"issue":"5","key":"10.1016\/j.cpcardiol.2024.102372_bib0035","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.36660\/abc.20201006","article-title":"Brazilian cardio-oncology guideline - 2020","volume":"115","author":"Hajjar","year":"2020","journal-title":"Arq Bras Cardiol"},{"issue":"36","key":"10.1016\/j.cpcardiol.2024.102372_bib0036","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"41","key":"10.1016\/j.cpcardiol.2024.102372_bib0037","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.cpcardiol.2024.102372_bib0038","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation [Internet]."},{"key":"10.1016\/j.cpcardiol.2024.102372_bib0039","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jchf.2022.04.014","article-title":"Sodium-glucose co-transporter-2 inhibitor therapy during anthracycline treatment: is there a role for cardioprotection?","volume":"10","author":"Khouri","year":"2022","journal-title":"JACC. Heart Failure. United States"},{"key":"10.1016\/j.cpcardiol.2024.102372_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.863314","article-title":"Novel therapeutics for anthracycline induced cardiotoxicity","volume":"9","author":"Vuong","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2024.102372_bib0041","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10549-014-3253-7","article-title":"Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer","volume":"149","author":"Yu","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.cpcardiol.2024.102372_bib0042","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","article-title":"Sodium-glucose Co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines","volume":"10","author":"Gongora","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10.1016\/j.cpcardiol.2024.102372_bib0043","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/heartjnl-2022-321545","article-title":"Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer","volume":"109","author":"Chiang","year":"2023","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102372_bib0044","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaccao.2023.03.011","article-title":"The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer","volume":"5","author":"Abdel-Qadir","year":"2023","journal-title":"JACC CardioOncology"},{"key":"10.1016\/j.cpcardiol.2024.102372_bib0045","article-title":"SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction","author":"Avula","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"Supplement_D","key":"10.1016\/j.cpcardiol.2024.102372_bib0046","article-title":"P470 berberine associated to dapagliflozin exerts synergistic cardioprotective effects in cardiac cells exposed to the her2\u2013bloking agent trastuzumab through pampk activation and reduction in interleukin\u20136 levels","volume":"25","author":"Quagliariello","year":"2023","journal-title":"Eur Hear J"},{"issue":"Supplement_D","key":"10.1016\/j.cpcardiol.2024.102372_bib0047","article-title":"C12 dapagliflozin increases pampk and reduces myocardial and renal nf\u2013kb expression in preclinical models of short\u2013term doxorubicin cardiotoxicity through myd\u2013188 and nlrp3 pathways","volume":"25","author":"Quagliariello","year":"2023","journal-title":"Eur Hear J"},{"issue":"16_suppl","key":"10.1016\/j.cpcardiol.2024.102372_bib0048","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2022.40.16_suppl.587","article-title":"Dapagliflozin associated to sacubitril\/valsartan and relationship with cardioprotection in human cardiac cells exposed to doxorubicin and HER2-blocking agents through MyD88, NLRP3 mediated pathways","volume":"40","author":"Maurea","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2024.102372_bib0049","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00204-020-02951-8","article-title":"Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"95","author":"Chang","year":"2021","journal-title":"Arch Toxicol"},{"issue":"Suppl_1","key":"10.1016\/j.cpcardiol.2024.102372_bib0050","article-title":"9383: dapagliflozin, an Sglt2 inhibitor, reduces expression of Myd88, Nlrp3 and Nf-kb during exposure to doxorubicin and trastuzumab in cellular models","volume":"144","author":"Maurea","year":"2021","journal-title":"Circulation [Internet]"},{"key":"10.1016\/j.cpcardiol.2024.102372_bib0051","doi-asserted-by":"crossref","first-page":"S1106","DOI":"10.1016\/j.annonc.2020.08.1361","article-title":"1969P The SGLT2 inhibitor dapagliflozin enhanced anticancer activities and exerts cardioprotective effects against doxorubicin and trastuzumab toxicity through TLR4, MyD88, NF-kB signaling and NLRP3 inflammasome pathway","volume":"31","author":"Maurea","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpcardiol.2024.102372_bib0052","doi-asserted-by":"crossref","DOI":"10.1007\/s10557-020-06941-x","article-title":"The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity","author":"Timm","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"10.1016\/j.cpcardiol.2024.102372_bib0053","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","article-title":"Dapagliflozin attenuates Na(+)\/H(+) exchanger-1 in cardiofibroblasts via AMPK activation","volume":"32","author":"Ye","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"issue":"12","key":"10.1016\/j.cpcardiol.2024.102372_bib0054","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.4161\/cc.7.12.6016","article-title":"Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells","volume":"7","author":"Shell","year":"2008","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.cpcardiol.2024.102372_bib0055","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40959-023-00172-3","article-title":"Mechanisms of trastuzumab induced cardiotoxicity \u2013 is exercise a potential treatment?","volume":"9","author":"Eaton","year":"2023","journal-title":"Cardio-Oncology"},{"issue":"12","key":"10.1016\/j.cpcardiol.2024.102372_bib0056","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.4070\/kcj.2019.0180","article-title":"Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure","volume":"49","author":"Oh","year":"2019","journal-title":"Korean Circ J"},{"key":"10.1016\/j.cpcardiol.2024.102372_bib0057","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.biopha.2018.10.095","article-title":"Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat","volume":"109","author":"Yang","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.cpcardiol.2024.102372_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121207","article-title":"Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis","volume":"312","author":"Min","year":"2023","journal-title":"Life Sci"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624000112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624000112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:54:14Z","timestamp":1758941654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280624000112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0146280624000112"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102372","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cardioprotective potential of sodium-glucose cotransporter 2-inhibitors in breast cancer therapy-related cardiac dysfunction \u2013 A systematic review","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102372"}}